Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBaylor Scott & White Medications Coverage & Prior …
    Ask Trek AI about this page
    CurrentBaylor Scott & White Health PlanPolicy 215

    Medications Covered Under Medical Insurance Policy

    Customize your policy alerts

    Sign up for Baylor Scott & White Health Plan Policy 215 alerts

    Get alerted when Policy 215 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity, prior authorization expectations, and general coverage criteria for medications administered by a medical professional when no more specific medical policy exists; applies to Baylor Scott & White Health Plan lines of business and related plan types.

    Policy Summary
    PayerBaylor Scott & White Health Plan
    PolicyMedications Covered Under Medical Insurance Policy
    Policy CodePolicy 215
    Change TypeNo material changes
    Effective DateMay 1, 2026
    Last ReviewApr 23, 2026
    Next Review DateApr 23, 2027
    Key ActionObtain prior authorization and supply diagnosis plus supporting medical record documentation when requesting coverage; use InterQual criteria when applicable.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsmax auth duration
    FDA-approved

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    FDA approval required
    InterQualInterQual referenced
    All reviewedCellular & gene review

    Coverage Criteria

    Medical necessity criteria

    Covered when ALL of the following are met

    Prescriber expertise: The medication is prescribed by or in consultation with a specialist that has expertise in the applicable disease or condition.

    from policy

    Documentation: The indicated diagnosis supplied in the request (including any applicable labs and/or tests) and medication usage is supported by documentation from the patient’s medical records.

    from policy

    FDA approval: The drug is approved by the FDA for at least ONE indication.

    from policy

    Accepted indication evidence: One of the following: - (a) The member meets the applicable criteria set in InterQual® if the medication requires prior authorization (applicable criteria set = a drug subset with clinical criteria for the requested indication or condition). Note: All InterQual® subsets with a final recommendation requiring additional review must be reviewed by a clinical pharmacist and medical director. - (b) Use of the drug for the diagnosis is supported in a standard drug reference compendium (e.g., AHFS-DI with supportive narrative, NCCN Drugs and Biologics Compendium, Thomson Micromedex DrugDex with Strength of Recommendation Class IIb+ and Strength of Efficacy Class IIa+, or Clinical Pharmacology) OR - (c) The safety and effectiveness for the indication has been demonstrated by at least two well-designed controlled clinical trials published in a nationally recognized peer-reviewed medical journal. Clinical trials supporting off-label indications must be supplied with the request.

    captures InterQual, compendia, and trials pathways

    Dosing and regimen: The medication is being used within an FDA-approved dosing regimen as stated in the product labeling, including recommended initiation dosing. Following initial dosing, increases in dose or frequency require documented trial and failure of standard FDA-approved dosing and frequency; use beyond FDA labeling maximum dosages not supported by labeling, compendia, or peer-reviewed evidence is considered unproven and may not be medically necessary.

    from policy

    Non-preferred agents / step therapy: For medications with a non-preferred status, the member must have failure of an adequate trial of, or clinically significant intolerance/contraindication to, ALL preferred drugs in the same class that can be used for the requested indication (see BSWHP policies 306 and 307).

    from policy

    Continuation expectations: Continuation of therapy requires clinical documentation showing continued use and dosing are consistent with the above criteria and evidence of improvement, stabilization of disease, or a reduction in expected decline, with manageable or no side effects.

    from policy

    Medications that were approved under the FDA's accelerated approval pathway but for which the indication was subsequently withdrawn by the FDA are not considered medically necessary and are excluded from coverage.

    Requests for drug use for indications that are not supported by recognized compendia or by sufficient clinical trial evidence may be considered unproven, experimental, and investigational and therefore not medically necessary. The policy requires either support in a standard drug reference compendium (for example AFHS‑DI, NCCN Drugs and Biologics Compendium, DrugDex, Clinical Pharmacology) or demonstration of safety and effectiveness by at least two well‑designed controlled clinical trials when relying on the evidence pathway.

    Coding / Billing

    Applicable codes (not enumerated)mixed
    CPT Codes:Not enumerated in policy; list may apply depending on medication and service
    HCPCS Codes:Not enumerated in policy; list may apply depending on medication and service
    ICD10 codes:Not enumerated in policy; inclusive list may not be presented
    ICD10 Not covered:Not enumerated

    Provider Actions & Authorization

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for medications covered under this policy when the member’s plan or the drug’s coverage pathway indicates PA. Applicable InterQual® criteria will be used when available to evaluate requests that require prior authorization.

    • Prior authorization requirement varies by line of business—see member EOC/SPD for specifics.
    • For Medicare, follow applicable NCDs/LCDs when present; if none apply, use policy criteria and InterQual® where specified.
    • InterQual® subsets that return a final recommendation of 'requires additional review' will be escalated to a clinical pharmacist and medical director.
    Denial Risk

    Unproven Indications — Denial Risk

    Requests for indications that are not supported by accepted drug compendia or by at least two well-designed clinical trials may be considered unproven and are at risk for denial.

    Background

    Many medications have specific FDA‑approved dosing parameters, including recommended initial and maximum dosages. Use outside those labeled regimens (off‑label or unlabeled use) may be considered medically necessary only when supported by recognized compendia or sufficient peer‑reviewed evidence. When a medication that requires prior authorization aligns with an applicable InterQual® subset, that subset should be used to assess medical necessity; InterQual recommendations that require additional review are escalated to a clinical pharmacist and medical director as part of the authorization process.

    Definitions

    Off‑label (unlabeled) drug use — definition and context
    DefinitionUse of a drug approved by the FDA for indications, regimens, or patient populations not included in the FDA‑approved labeling (i.e., use for an indication other than those listed in the drug's labeling).
    Regulatory contextFDA approves drugs for specific labeled indications; off‑label use occurs when a drug is used for an indication not included in that labeling.
    Evidence considerationsMany off‑label uses are effective and well‑documented in the literature; however, unlabeled uses range from unstudied to thoroughly investigated scenarios where FDA approval was not sought.
    Relation to compendia/evidenceOff‑label uses may be supported by national compendia or peer‑reviewed resources and can be considered medically necessary when such evidence exists.
    Coverage implicationUnapproved or unlabeled uses lacking adequate evidence may be considered unproven/experimental and not medically necessary per policy criteria.

    Initial Therapy Criteria

    Initial therapy

    Initial coverage requirements when no specific policy exists

    Prescriber and FDA approval: Medication must be prescribed by or in consultation with a specialist and the drug must be approved by the FDA for at least one indication.

    from policy

    Evidence pathway for indication: If the medication requires prior authorization and an applicable InterQual® subset exists, the member must meet those InterQual criteria (applicable subset = drug subset with clinical criteria for the requested indication). OR if no applicable InterQual subset exists, the requested diagnosis must be an FDA-approved indication or an accepted off-label use supported by a standard drug compendium (e.g., AHFS-DI, NCCN, Micromedex, Clinical Pharmacology) or by at least two well-designed controlled clinical trials published in a peer-reviewed journal. Clinical trial evidence for off-label use must be supplied with the request.

    captures InterQual, compendia, and trials pathways

    Dosing: Use must be within FDA-approved dosing and initiation recommendations. Dose increases or more frequent dosing beyond standard FDA-approved dosing require documentation of prior trial and failure of standard dosing.

    Continuation / Renewal Criteria

    Continuation therapy

    Continuation/renewal requirements

    Consistency with initial criteria: Continued use of the drug and dosing must be consistent with the initial criteria above.

    from policy

    Clinical benefit: Documentation must show improvement, stabilization of disease, or a reduction in expected decline for the applicable population.

    from policy

    Tolerability: Side effects must be manageable or absent as documented in the medical record.

    from policy

    Step Therapy

    StepRequirementReference / Notes
    1For non-preferred medications, member must have trial and failure of an adequate trial of all preferred drugs in the same class or documentation of clinically significant intolerance or contraindication.See BSWHP step therapy policies 306 and 307 for specific step requirements and definitions; InterQual® criteria apply when prior authorization is required.
    2Provider must supply supporting documentation from the patient’s medical record, including the indicated diagnosis, applicable labs/tests, and specialist consultation as appropriate to demonstrate failure/intolerance and medical necessity.Policy requires documentation per Med. Necessity criteria; see policy notes on required documentation and prior authorization processes.
    3If the medication requires prior authorization and an applicable InterQual® subset exists, the member must meet InterQual® criteria; InterQual® subsets with a final recommendation requiring additional review will be reviewed by a clinical pharmacist and medical director.InterQual® applicability and review escalation referenced in policy; see policy history and InterQual® clarification.

    Site of Care

    Note

    Confirm infusion‑site indication and per‑administration dosing

    This policy provides indications and maximum dosage per administration for medications administered by a medical professional; when requesting medications given in an infusion or clinic setting, ensure the indication and dosing per administration align with the policy documentation.

    • Site-specific rules and maximum per-administration doses are provided in this policy for medications administered by a medical professional.
    Policy Summary
    PayerBaylor Scott & White Health Plan
    PolicyMedications Covered Under Medical Insurance Policy
    Policy CodePolicy 215
    Change TypeNo material changes
    Effective DateMay 1, 2026
    Last ReviewApr 23, 2026
    Next Review DateApr 23, 2027
    Key ActionObtain prior authorization and supply diagnosis plus supporting medical record documentation when requesting coverage; use InterQual criteria when applicable.
    SourceLink
    On This Page
    Coverage CriteriaCoding / BillingProvider Actions & AuthorizationBackgroundDefinitionsInitial Therapy CriteriaContinuation / Renewal CriteriaStep TherapySite of Care
    • Standard drug reference compendia accepted include AHFS Drug Information, NCCN Drugs & Biologics Compendium, Thomson Micromedex DrugDex (Strength of Recommendation Class IIb or better and Strength of Efficacy Class IIa or better), and Clinical Pharmacology.
    • If the requested use is not represented in these compendia or lacks adequate clinical trial evidence, the request may be denied as not medically necessary.
    Documentation Required

    Required Documentation

    Providers must supply the diagnosis and supporting documentation with the prior authorization request. Supporting documentation should include relevant clinical notes, diagnostic test results, and laboratory data demonstrating medical necessity.

    • Provide the indication/diagnosis and relevant labs/tests in the request.
    • Include clinical notes that document prior therapies, response, intolerance, or contraindications when applicable.
    • For Medicaid members in Texas, confirm any additional documentation required per TMHP/TMPPM and Texas Mandate HB154.

    from policy

    Step therapy: For non-preferred medications, member must have trial and failure or clinically significant intolerance/contraindication to all preferred drugs in the same class (see policies 306 and 307).

    from policy